Online Lifestyle Magazine for Healthcare Workers by Pulse Uniform

Latest Study to Test Effectiveness of Cannabis to Treat Pancreatic Cancer

Cannabis has long been utilized for hemp oils, hemp fiber, and many other functional purposes.  Moreover, it has also been used as a recreational drug causing addiction. However, the drug has many health benefits and been used for various medical and pharmaceutical purposes as well. PERTH research are to test and analyze whether medical cannabis can prove to be a breakthrough in the cure for pancreatic cancer, one of the most fatal health disorders on the planet earth.

School of Biomedical Science of Curtin University is prepared to begin testing cannabis formulations and evaluating its power against pancreatic cell cancer lines of humans grown in the laboratory. The research is in collaboration with a Perth-based biopharmaceutical organization, viz. Zelda Therapeutics, which will import the drug from Canada. The project will diligently examine the effectiveness of cannabis formulations as standalone cures and in combination with available chemotherapy drugs, e.g. Abraxane.

Pancreatic cancer is often difficult to recognize in its early stages which is highly aggressive and the eleventh most common cancer identified in Australia. Studies have shown that only 6 percent of the sufferers survive up to five years post diagnosis. Marco Falasca, Curtin University’s Professor, said that after many years of sluggish progress in the area of pancreatic cancer treatment, they expect to finally discover the path to innovative therapies for the lethal disease.

Zelda told that the research would seek to replicate the success results of its cannabinoid formulations aimed to treat breast cancer. Moreover, in November, Zelda made the announcement of the outcomes of an experimental trial, and claimed its THS-rich medical cannabis formula as an effective ingredient, viz. chemotherapy drug Lapatinib, in reducing breast cancer tumor expansion in mice. However, the results still demand clinical trial validation.

Harry Karellis, Zelda’s executive chairman, hoped that the research would demonstrate anti-cancer activity. Up until now Professor Falasca has been working with synthetic cannabidiol and producing positive data in vivo and in vitro. The whole program would be testing Zelda’s whole plant extracts in its established cell assays, and depending upon the outcomes could progress into extended work in animal models. For the research trials, AusCann will obtain the research content from its Canadian partner Canopy Growth Corporation which is the world’s leading medical cannabis cultivator.

We hope that the research would bring effective treatment results and open the pathways to new and efficient therapies to cure pancreatic cancer.

Post Tagged with , , ,

About admin